Sac/Val Does Not Significantly Raise B-type Natriuretic Peptide in HFrEF Patients
According to findings in a study published in the Journal of the American College of Cardiology: Heart Failure, researchers indicated that there were no reports of significant increases in overall B-type natriuretic peptide (BNP) concentrations in patients with heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan (Sac/Val). Additionally, patients demonstrated increases in urinary cyclic guanosine monophosphate regardless of the trajectory of BNP change. Read more.

Global Assessment Reveals HoFH Frequently Undertreated
In a recent study, researchers attempted to evaluate the clinical and genetic characteristics, as well as the global impact, of current practice on health outcomes of the rare, inherited disorder known as homozygous familial hypercholesteremia (HoFH). Researchers indicated that HoFH is often undertreated—especially in lower income countries—and is sometimes diagnosed after atherosclerosis or aortic stenosis is already present. Read more.

FDA Approves Twice-Yearly Injectable Drug to Lower LDL-C Levels
The manufacturer, Novartis, announced that the FDA approved Leqvio (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (LDL-C) with two doses a year after an initial dose and 1 at 3 months in patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. Learn more about this first-of-its-kind siRNA therapy.